Patent intelligence · US
US 9718841
Bicyclic pyrazolone compounds and methods of use
Bicyclic pyrazolone compounds and methods of use
Patent details — US 9718841
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 1, 2017
- Expiration
- Jul 27, 2037
- Applicant
- SUNSHINE LAKE PHARMA CO., LTD.
- Claims
- 19
- CPC classes
- A61K, A61K31/437, A61K31/4439, A61K31/444
Quick answer
US 9718841 (Bicyclic pyrazolone compounds and methods of use) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Aug 1, 2017. Expires Jul 27, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SUNSHINE LAKE PHARMA CO., LTD.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/437, A61K31/4439, A61K31/444, A61K31/5383, A61K31/5395
More from SUNSHINE LAKE PHARMA CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12428432
Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
granted -
US 12428389
Diarylamide compound and application thereof
granted -
US 12384853
Anti-HER2/PD1 bispecific antibody
granted -
US 12324812
Glucopyranosyl derivatives and their uses
granted -
US 12319748
Antibody binding to human HER2 and preparation method and use thereof
granted -
US 12312348
RET inhibitors, pharmaceutical compositions and uses thereof
granted -
US 12269886
Tetravalent bispecific antibody against PD-1 and PD-L1
granted -
US 12258317
Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof
granted
Frequently asked questions
What is US patent 9718841?
US 9718841 (Bicyclic pyrazolone compounds and methods of use) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Aug 1, 2017. Expires Jul 27, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9718841?
SUNSHINE LAKE PHARMA CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 121 pharmaceutical patents for this assignee.
When does US 9718841 expire?
Our index shows an expiration date of Jul 27, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.